Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361395 · ClinicalTrials.gov registry record · Phase 1
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT05361395: Active Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
NCT05361395 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 184 participants, above the 168-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05361395, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Etoposide
- DRUG Durvalumab
- DRUG Tarlatamab
Study Locations (20)
Other
- Universitair Ziekenhuis Antwerpen - Edegem
- Algemeen Ziekenhuis Maria Middelares - Ghent
- Jessa Ziekenhuis - Campus Virga Jesse - Hasselt
- AZ Delta Campus Rumbeke - Roeselare
- Rigshospitalet - Copenhagen
- Centre Leon Berard - Lyon
- Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec - Saint-Herblain
- Gustave Roussy - Villejuif
California
- University of Southern California, Norris Comprehensive Cancer Center - Los Angeles
Delaware
- Christiana Care Health Services - Newark
Michigan
- Henry Ford Health System - Detroit
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
South Dakota
- Avera Cancer Institute - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2028-08-28 |
| Phase | Phase 1 |
What the registry record for NCT05361395 still lists
NCT05361395 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 168-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05361395 names 20 study sites across 13 states, led by Other, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT05361395 about?
NCT05361395 is a clinical study titled "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)". This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
What is the current status of trial NCT05361395?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2022-08-24. Estimated completion is 2028-08-28.
What conditions does trial NCT05361395 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT05361395?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), Durvalumab (DRUG), Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT05361395?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05361395 being conducted?
This trial has 20 study locations across California, Delaware, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05361395's enrollment target sits among peer trials
184 10th of 25 higher than 16 of 25 other Extensive-stage Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RECRUITING · Phase 1
-
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
RECRUITING · Phase 1
-
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
RECRUITING · Phase 1
-
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
RECRUITING · Phase 1
-
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI